Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the treatment of topotecan hydrochloride
capsules combined with anlotinib hydrochloride capsules in Patients with platinum-resistant
recurrent epithelial ovarian cancer. The main questions it aims to answer are: to assess the
objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR),
duration of response (DOR), overall survival (OS) and safety of topotecan hydrochloride
capsules combined with anlotinib hydrochloride capsules in patients with platinum-resistant
recurrent epithelial ovarian cancer.The treatment of participants： Topotecan hydrochloride
capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is,
21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib
hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for
14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
Receiving optimal supportive care at the same time until disease
progression/death/intolerable toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine